At the 33.8-month median follow-up

Overall survival (OS) of Opdualag vs nivolumab
 

Reference: 

1. Data on file. BMS-REF-NIVO+RELA-0014. Princeton, NJ: Bristol-Myers Squibb Company; 2023.

Median follow-up 33.8 months¹
Opdualag vs nivolumab PFS, OS and ORR by subgroups^* 
 

^*ITT-population. EU approved indication: PD-L1 <1%.

^aMeasurements shown are the sums of the reference diameters of the target lesions. bM1 HR and 95% CI were not calculated due to small patient numbers.

PFS = progression free survival; OS = overall survival; ORR = objective response rate

1. Supplementary appendix to Tawbi HA, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 (2024). Journal of Clinical Oncology. https://doi.org/10.1200/JCO.24.01124.